| 1.16 -0.03 (-2.52%) | 06-10 11:07 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.83 | 1-year : | 2.14 |
| Resists | First : | 1.57 | Second : | 1.83 |
| Pivot price | 1.2 |
|||
| Supports | First : | 1.06 | Second : | 0.75 |
| MAs | MA(5) : | 1.22  |
MA(20) : | 1.15 |
| MA(100) : | 0.88 |
MA(250) : | 1.35 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 39.8 |
D(3) : | 43.8 |
| RSI | RSI(14): 55.9 | |||
| 52-week | High : | 2.39 | Low : | 0.67 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IMRN ] has closed above bottom band by 47.7%. Bollinger Bands are 99.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 15 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.2 - 1.21 | 1.21 - 1.22 |
| Low: | 1.1 - 1.11 | 1.11 - 1.12 |
| Close: | 1.17 - 1.19 | 1.19 - 1.2 |
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products. Travelan is an over-the-counter (OTC) medicine that helps reduce the risk of traveler's diarrhea and lessens symptoms of minor gastrointestinal issues, while also serving as a dietary supplement for digestive tract protection. Its second product, Protectyn, is an immune supplement formulated to support healthy digestive function and liver health. In its pipeline, an advanced formulation of Travelan (IMM-124E) is undergoing Phase III clinical trials. This variant is being developed not only to further reduce the risk of traveler's diarrhea but also for its potential anti-viral activity against SARS-CoV-2. Another pipeline candidate, IMM-529, is in clinical development with a focus on treating recurrent Clostridium difficile infections. Immuron maintains strategic collaborations, including a research agreement with the Naval Medical Research Center to develop and clinically assess a therapeutic targeting Campylobacter and ETEC infections. Additionally, it has a collaboration with the Walter Reed Army Institute of Research aimed at creating an oral therapeutic for shigellosis. Established in 1994, Immuron Limited is headquartered in Carlton, Australia.
Tue, 02 Jun 2026
Immuron (ASX: IMC): Advancing Gastrointestinal Product Portfolio Across Multiple Markets - Kalkine Media
Thu, 28 May 2026
Immuron (NASDAQ: IMRN) responds to ASX query on share price - Stock Titan
Thu, 14 May 2026
Immuron (IMRN) CCO reports 1.14M shares and 640K performance rights in Form 3 - Stock Titan
Thu, 14 May 2026
Immuron (IMRN) director discloses shareholdings and long-dated options - Stock Titan
Fri, 17 Apr 2026
Immuron Double Digit 3Q Sales Growth - GlobeNewswire
Mon, 15 Dec 2025
Immuron (IMRN) Struggles After Announcing Trial Results - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 320 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 1 (%) |
| Shares Short | 26 (K) |
| Shares Short P.Month | 12 (K) |
| EPS | -0.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.14 |
| Profit Margin | -62.2 % |
| Operating Margin | -47.2 % |
| Return on Assets (ttm) | -22 % |
| Return on Equity (ttm) | -39.7 % |
| Qtrly Rev. Growth | 4.8 % |
| Gross Profit (p.s.) | 0.58 |
| Sales Per Share | 0.91 |
| EBITDA (p.s.) | -0.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -2.25 |
| PEG Ratio | 0 |
| Price to Book value | 1.03 |
| Price to Sales | 1.29 |
| Price to Cash Flow | -2.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|